Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.37 |
| ▸ | GCGR | P47871 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299677 | 0.92 | ESR1 (0.38) | TP53KDM4EMAPT | |
| SCHEMBL2300694 | 0.92 | TLR8 (0.39) | TLR8GCGRENPP2CNR1CNR2 | |
| SCHEMBL2299443 | 0.90 | TLR8 (0.38) | TLR8GCGRKDM4EMAPT | |
| SCHEMBL2298814 | 0.90 | KDM4E (0.42) | TLR8GCGRTP53CNR2KDM4E | |
| SCHEMBL3399430 | 0.89 | GCGR (0.33) | TLR8GCGRKDM4EMAPTSIRT2 | |
| SCHEMBL2297291 | 0.89 | GRM5 (0.38) | TLR8ENPP2CNR1CNR2SIRT2 | |
| SCHEMBL2298472 | 0.89 | RIPK3 (0.35) | TLR8LMNACNR2KDM4EMAPT | |
| SCHEMBL2298083 | 0.89 | TLR8 (0.37) | TLR8ENPP2TP53CNR1CNR2 | |
| SCHEMBL2298208 | 0.88 | TLR8 (0.34) | TLR8CNR2KDM4EMAPTSIRT2 | |
| SCHEMBL2298485 | 0.88 | PDE4B (0.42) | TLR8TP53LMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312975-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | YANG ZHE (US) | 2011-12-22 | — | — | US | claimed |
| EP-2244711-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Incorporated (US) | 2010-11-03 | — | — | EP | claimed |
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED | 2009-10-08 | — | — | US | claimed |
| WO-2009099594-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-08-13 | — | — | WO | claimed |
| US-20110312975-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | YANG ZHE (US) | 2011-12-22 | — | — | US | disclosed |
| US-7989469-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TNNC1, TNNI3, TNNT2 | TLR8 4623/4885GCGR 1346/4885ENPP2 2802/4885 |
| US-20110312975-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | TLR8 4634/4885GCGR 1276/4885ENPP2 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.